Does lkb1 mediate activation of hepatic amp-protein kinase (ampk) and sirtuin1 (sirt1) after roux-en-y gastric bypass in obese rats?

Journal of Gastrointestinal Surgery

Volumn 14, Issue 2, 2010, Pages 221-228

  Peng, Yanhua ^a   Rideout, Drew A ^a   Rakita, Steven S ^a   Gower Jr , William R ^a   You, Min ^b   Murr, Michel M ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

AMPK; LKB1; Obesity; Roux en Y gastric bypass; SIRT1

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PROTEIN SERINE THREONINE KINASE; SIRT1 PROTEIN, RAT; SIRTUIN 1; STK11 PROTEIN, RAT;

ANIMAL; ARTICLE; DISEASE MODEL; MALE; METABOLISM; OBESITY; RAT; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; STOMACH BYPASS;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; DISEASE MODELS, ANIMAL; GASTRIC BYPASS; MALE; OBESITY; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SIRTUIN 1;

EID: 77951899646     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-009-1102-5     Document Type: Article

References (42)

1. Shalhub S, Parsee A, Gallagher S. The importance of routine liver biopsy in diagnosing nonalcoholic steatohepatitis in bariatric patients. Obes Surg 2004; 14: 54-59.
2. Parsee A, Keshishian J, Torrella T, Wheeler D, Murr M. Outcomes in bariatric surgery: improvement in steatohepatitis and liver fibrosis. ASMBS 2009.
3. Kral J, Thung S, Biron S et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004; 135(1): 48-58.
4. Rideout D, Rakita S, Peng Y, Gower W, Murr M. Practical considerations and survival techniques for a rat model of Roux-en-Y gastric bypass. Gastroenterology 2008; 134(4): S1: A877.
5. Peng Y, Rideout D, Rakita S et al. Downregulation of adiponectin/AdipoR2 is associated with hepatic inflammation and steatosis in obese mice. Gastroenterology 2008; 134(4): S1: A851.
6. Rideout D, Peng Y, Rakita S, Gower W, You M, Murr M. Roux-en-Y gastric bypass improves obesity-related steatosis and does not increase serum adiponectin. JACS 2008; 207(3): S53.
7. Rideout D, Peng Y, Rakita S, Gower W, You M, Murr M. Roux-en-Y gastric bypass downregulates hepatic stearoyl-CoA desaturase 1 independently of serum leptin in obese rats. J Surg Res. 2009; 151(2): 244.
8. Peng Y, Rideout D, Rakita S et al. Roux-en-Y gastric bypass reduces oxidative stress and down regulates pro-inflammatory genes in livers of obese rats and in Kupffer cells via an AMPK-dependent pathway. J Surg Res. 2009; 151(2): 244-245.
9. Canto C, Auwerx J. PGC-1a, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 2009; 20: 98-105.
10. Cantó C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, Elliott PJ, Puigserver P, Auwerx J. AMPK regulates enery expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 2009; 458(7241): 1056-1060.
11. Witczak C, Sharoff C, Goodyear L. AMP-activated protein kinase in skeletal muscle: from structure and localization to its role as a master regulator of cellular metabolism. Cell Mol Life Sci 2008; 65(23): 3737-3755.
12. Hou X, Xu S, Maitland-Toolan K et al. SIRT1 regulates hepatocyte lipid metabolism through acting AMPK. J Biol Chem 2008; 283(29): 20015-20026.
13. Sanz P. AMP-activated protein kinase: structure and regulation. Curr Protein Pept Sci 2008; 9(5): 478-492.
14. Auwwerx J, Canto C. PGC-alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 2009; 20(2): 98-105.
15. Feige J, Lagouge M, Canto C et al. Specific SIRT1 activation mimics energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab 2008; 8(5): 347-358.
16. Metoyer C, Pruitt K. The role of sirtuin protein in obesity. Pathophysiology 2008; 15: 103-108.
17. You M, Liang X, Ajmo J, Ness G. Importance of mammalian sirtuin 1 in the action of ethanol in the liver. Am J Physiol Gastrointest Liver Physiol 2008; 294: G892-G898.
18. Ajmo J, Liang X, Rogers C, Pennock B, You MAJPGLP. Resveratrol alleviates alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol 2008; 295(4): G833-G842.
19. Kyriakis J. At the crossroads: AMP-activated kinase and the LKB1 tumor suppressor link cell proliferation to metabolic regulation. J Biol 2003; 2(4): 26.
20. Song P, Xie Z, Wu Y, Xu J, Dong Y, Zou M. Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation increases LKB1 nucleus export and apoptosis in endothelial cells. J Biol Chem 2008; 283(18): 12446-12455.
21. Peng Y, Sigua C, Karsonovich C, Murr M. Protein kinase C-zeta (PKC-zeta) regulates Kupffer cell apoptosis during experimental sepsis. J Gastrointest Surg 2007; 11(12): 1712-1721.
22. Peng Y, Rideout D, Rakita S et al. Roux-en-Y gastric bypass reduces oxidative stress and down regulates pro-inflammatory genes in livers of obese rats and in Kupffer cells via an AMPK-dependent pathway. J Surg Res. 2009; 151(2): 244-245.
23. Woods A, Johnstone S, Dickerson K et al. LKB1 is the upstream kinase in AMP-activated protein kinase cascade. Curr Biol 2003; 13: 2004-2008.
24. Horton J. Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis. Biochem Soc Trans 2002; 30: 1091-1095.
25. Herrema H, Derks T, van Dijk T et al. Disturbed hepatic carbohydrate management during high metabolic demand in medium-chain acyl-CoA dehydrogenase (MCAD)-deficient mice. Hepatology 2008; 47(6): 1894-1904.
26. Kelly T, Lerin C, Haas W, Gygi S, Puigserver P. GCN5-mediated transcriptional control of the metabolic coactivator PGC1a through lysine acetylation. J Biol Chem 2009; 284(30): 19945-19952.
27. Thomson D, Winder W. AMP-activated protein kinase control of fat metabolism in skeletal muscle. Acta Physiol (Oxf) 2009; 196(1): 147-154.
28. Shaw R, Lamia K, Vasquez D et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310(5754): 1642-1646.
29. Zhou G, Sebhat I, Zhang B. AMPK activators-potential therapeutics metabolic and other diseases. Acta Physiol (Oxf). 2009; 196(1): 175-190.
30. Gruzman A, Babai G, Sasson S. Adenosine monophosphate-activated protein kinase (AMPK) as a new target for antidiabetic drugs: a review on metabolic, pharmacological and chemical considerations. Rev Diabet Stud 2009; 6(1): 13-36.
31. Mulligan J, Carey H, Saupe K. Upregulation of AMPK during cold exposure occurs via distinct mechanism in brown and white adipose tissue of the mouse. J Physiol 2007; 580(2): 677-684.
32. Winder W, Hardie D. The AMPK, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 1999; 277: E1-E10.
33. Zhou G, Myers R, Li Y. Role of AMPK in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174.
34. Xie Z, Dong Y, Scholz R, Neumann D, Zou M. Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation 2008; 117(7): 952-962.
35. Song P, Xie Z, Wu Y, Xu J, Dong Y, Zou M. Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation increases LKB1 nucleus export and apoptosis in endothelial cells. J Biol Chem 2008; 283(18): 12446-12455.
36. Xie Z, Dong Y, Zhang M et al. Activation of protein kinase C zeta by peroxynitrite regulates LKB1-dependent AMP-activated protein kinase in cultured endothelial cells. J Biol Chem 2006; 281(10): 6366-6375.
37. Ussher J, Jaswal J, Wagg C et al. Role of the atypical protein kinase Czeta in regulation of 5'-AMP-activated protein kinase in cardiac and skeletal muscle. Am J Physiol Endocrinol Metab 2009; 297(2): E349-E357.
38. Sasaki T, Maier B, Koclega K et al. Phosphorylation regulates SIRT1 function. PLoS ONE 2008; 3(12): e4020.
39. Lan F, Cacicedo J, Ruderman N, Ido Y. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LBK1: possible role in AMPK-activated protein kinase activation. J Biol Chem 2008; 283(41): 27628-27635.
40. Shackelford D, Shaw R. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009; 9(8): 563-575.
41. Awazawa M, Ueki K, Inabe K et al. Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathway. Biochem Biophys Res Commun 2009; 382(1): 51-56.
42. Zhou L, Deepa S, Etzler J et al. Adiponectin activates AMP-activated protein kinase in muscle cells via APPL1/LKB1-dependent and phospholipase C/Ca2+/Ca2+/calmodulin-dependent protein kinase kinase-dependent pathways. J Biol Chem 2009; 284(33): 22426-22435.